Owlet, Inc.

NYSE:OWLT

Medical - Devices

Healthcare
$3.67 +9.76%

+$0.46 today

Market cap
$107.24M
Beta
1.86
P/E (TTM)
-0.4
EPS (TTM)
-$12.67
52W Low $4.19High $16.94

Volume 0.64M

Average 0.24M

OWLT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Owlet, Inc.NYSE: OWLT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $185K rose 25.0% year over year, ahead of the -41.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 12.1% from the prior quarter. Over 3 fiscal years it compounded at -39.6% a year.

Context

  • Depreciation & amortization amounted to 0.6% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.0% holds above the trailing-twelve-month pace of -41.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$185K+12.1% QoQ
Last fiscal yearDec 2025
$590K-57.3% YoY
LTMMar 2026
$627K-41.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.0%——
1 year-57.3%——
3-year CAGR-39.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
590K USD
Year-over-year change
-57.3%
4-year CAGR
-15.1%

Depreciation & Amortization vs competitors

How OWLT compares with its peers on the latest reported figures

  • OWLT's LTM Mar 2026 depreciation & amortization of $627K is the 9th largest of the 10 companies compared; the peer median is $3.11M.
  • Its year-over-year change of -41.1% is the 9th highest of 10, against a peer median of +4.5%.
  • Depreciation & amortization amounts to 0.6% of revenue for OWLT, versus a peer median of 14.5%.
OWLT Competitors Peer median
Depreciation & Amortization for OWLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$429.44M +48315.3%-23.3%8364.7%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$5.54M -27.5%-26.6%4.8%
MXCTMaxCyte, Inc.LTM Mar 2026$4.68M +4.5%+24.0%14.5%
LNSRLENSAR, Inc.LTM Mar 2026$4.56M +11.6%+9.7%7.9%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$3.11M -8.6%+4.7%9.0%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.69M +7.8%+29.0%91.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$1.17M +120.2%+56.5%222.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$1.14M -2.3%+2.2%—
OWLTOwlet, Inc.LTM Mar 2026$627K -41.1%-39.6%0.6%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$287K -146.9%——
Peer median (excluding OWLT) $3.11M+4.5%+7.2%14.5%

Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.7M)(79.34M)(32.9M)(12.54M)(38.46M)
Depreciation & Amortization1.13M2.67M2.21M1.38M590K
Deferred Income Tax00000
Stock-Based Compensation4.26M12.86M9.93M8.63M9.35M
Change in Working Capital9.45M(15.2M)(4.82M)(2.52M)(10.71M)
Accounts Receivables(144K)(8.5M)965K2.03M(10.97M)
Inventory(11.65M)(1.18M)12.12M(4.14M)(4.93M)
Accounts Payables32.12M(10.72M)(19.5M)1.32M5.43M
Other Working Capital(10.87M)5.2M1.6M(1.74M)(236K)
Other Non-Cash Items16.3M(2.37M)2.05M(6.16M)28.43M
Operating Cash Flow(40.56M)(81.38M)(23.53M)(11.21M)(10.8M)
Capital Expenditures(2.02M)(1.57M)(59K)(761K)(273K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(1.05M)(929K)(43K)(726K)0
Investing Cash Flow(2.02M)(1.57M)(59K)(761K)(943K)
Debt Repayment(3.49M)(1.5M)156K(816K)55K
Common Stock Issued00010M34.69M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities124.11M618K269K(2M)(2.64M)
Financing Cash Flow120.62M(878K)28.91M16.04M32.1M
Effect of Forex Changes00000
Net Change in Cash78.05M(83.82M)5.33M4.07M20.38M
Free Cash Flow(42.58M)(82.95M)(23.59M)(11.97M)(11.07M)

Owlet, Inc.

NYSE:OWLT

Intrinsic Alpha fair value

Locked

Current Price

$3.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.